Prism Advisors’s ADMA Biologics ADMA Stock Holding History

Prism Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-19,404	Closed	-$128K	–	65
2024 Q1	$128K	Buy	+19,404	New	+$106K	0.04%	58

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prism Advisors's ADMA Position: Q2 2024 in Review

Prism Advisors sold out of ADMA Biologics (ADMA) in Q2 2024, closing a stake of 19,404 shares — an estimated $128K sold.

Prism Advisors first reported a position in ADMA in Q1 2024 and held it in 1 quarter. The position peaked at $128K in Q1 2024. 252 funds tracked by Wall St. Rank hold ADMA as of Q2 2024.

Prism Advisors reported no remaining ADMA Biologics position as of Q2 2024 after selling out during the quarter.
Prism Advisors sold 19,404 ADMA Biologics shares in Q2 2024, an estimated $128K.
Prism Advisors first reported a position in ADMA Biologics in Q1 2024 and held it in 1 quarter.
Prism Advisors's ADMA Biologics position peaked at $128K in Q1 2024.
252 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2024.

Based on Prism Advisors's 13F filing for Q2 2024, filed 10 Jul 2024.